Literature DB >> 31745840

Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.

Claudio Borghi1,2, Alberto Palazzuoli3, Matteo Landolfo4, Eugenio Cosentino4.   

Abstract

Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden. Hyperuricemia is an old emerging metabolic disorder, and interaction among uric acid and cardiovascular diseases has been clearly described. Several illness including hypertension, myocardial infarction, metabolic syndrome, and heart failure, are related with uric acid levels increase. In this review, we will discuss the pathophysiology of hyperuricemia and describe the biological plausibility for this metabolite to participate in the pathogenesis of cardiovascular disorders. In particular, we will focus on the implications of hyperuricemia in the onset and progression of heart failure, paying special attention to the pathophysiology and the possible clinical implications. We will conclude by discussing the effects of lowering plasma uric acid concentration on the prognosis of heart failure by reviewing most of available data on the different classes of drugs directly or indirectly involved in the hyperuricemia management.

Entities:  

Keywords:  Cardiovascular diseases; Heart failure; Uric acid; Xanthine oxidase

Mesh:

Substances:

Year:  2020        PMID: 31745840     DOI: 10.1007/s10741-019-09869-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  92 in total

Review 1.  Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

2.  Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Robert J Mentz; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Karl Swedberg; Faiez Zannad; Marvin A Konstam; Michele Senni; Michael M Givertz; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-09-16       Impact factor: 2.778

3.  Hyperuricemia predicts adverse outcomes in patients with heart failure.

Authors:  Sanae Hamaguchi; Tomoo Furumoto; Miyuki Tsuchihashi-Makaya; Kazutomo Goto; Daisuke Goto; Takashi Yokota; Shintaro Kinugawa; Hisashi Yokoshiki; Akira Takeshita; Hiroyuki Tsutsui
Journal:  Int J Cardiol       Date:  2010-06-14       Impact factor: 4.164

4.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.

Authors:  A D Gavin; A D Struthers
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 6.  Uric acid: bystander or culprit in hypertension and progressive renal disease?

Authors:  Paolo Menè; Giorgio Punzo
Journal:  J Hypertens       Date:  2008-11       Impact factor: 4.844

7.  Inactivation of nitric oxide by uric acid.

Authors:  Christine Gersch; Sergiu P Palii; Kyung Mee Kim; Alexander Angerhofer; Richard J Johnson; George N Henderson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-08       Impact factor: 1.381

Review 8.  Chronic Heart Failure and Inflammation: What Do We Really Know?

Authors:  Sarah A Dick; Slava Epelman
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

9.  Uricaemia and ejection fraction in elderly heart failure outpatients.

Authors:  Claudio Borghi; Eugenio R Cosentino; Elisa R Rinaldi; Arrigo F G Cicero
Journal:  Eur J Clin Invest       Date:  2014-06       Impact factor: 4.686

10.  Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

Authors:  Thomas M MacDonald; Ian Ford; George Nuki; Isla S Mackenzie; Raffaele De Caterina; Evelyn Findlay; Jesper Hallas; Christopher J Hawkey; Stuart Ralston; Matthew Walters; John Webster; John McMurray; Fernando Perez Ruiz; Claudine G Jennings
Journal:  BMJ Open       Date:  2014-07-10       Impact factor: 2.692

View more
  7 in total

1.  Association of Sleep Duration with Hyperuricemia in Chinese Adults: A Prospective Longitudinal Study.

Authors:  Huan Yu; Kexiang Shi; Haiming Yang; Dianjianyi Sun; Jun Lv; Yuan Ma; Sailimai Man; Jianchun Yin; Bo Wang; Canqing Yu; Liming Li
Journal:  Int J Environ Res Public Health       Date:  2022-07-01       Impact factor: 4.614

2.  Katsuwonus pelamis Peptide and its Complexes Protect Zebrafish and Mice From Hyperuricemia Through Promoting Kidney Excretion of Uric Acid and Inhibiting Liver Xanthine Oxidase Activity.

Authors:  Wei Wei; Li-Jian Zhou; Shue Wang; Zheng Zhang; Jia-Ying Huang; Zhao Zhang; Xi-Ping Zhang; Xue-Jun Zhang; Jie Li; Ye-Wang Zhang
Journal:  Front Chem       Date:  2022-06-28       Impact factor: 5.545

3.  Higher Levels of High-Sensitivity C-Reactive Protein Is Positively Associated with the Incidence of Hyperuricemia in Chinese Population: A Report from the China Health and Retirement Longitudinal Study.

Authors:  Hui-Xu Dai; Zhi-Ying Zhao; Yang Xia; Qi-Jun Wu; Yu-Hong Zhao
Journal:  Mediators Inflamm       Date:  2020-05-20       Impact factor: 4.711

Review 4.  Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications.

Authors:  Min Gong; Song Wen; Thiquynhnga Nguyen; Chaoxun Wang; Jianlan Jin; Ligang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-30       Impact factor: 3.168

5.  U-Shaped Association Between Serum Uric Acid Level and Hypertensive Heart Failure: A Genetic Matching Case-Control Study.

Authors:  Hongxuan Xu; Quan Wang; Yunqing Liu; Lingbing Meng; Huanyu Long; Li Wang; Deping Liu
Journal:  Front Cardiovasc Med       Date:  2021-12-08

6.  Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.

Authors:  Kirsty McDowell; Paul Welsh; Kieran F Docherty; David A Morrow; Pardeep S Jhund; Rudolf A de Boer; Eileen O'Meara; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Ann Hammarstedt; Anna Maria Langkilde; Mikaela Sjöstrand; Daniel Lindholm; Scott D Solomon; Naveed Sattar; Marc S Sabatine; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2022-02-06       Impact factor: 17.349

Review 7.  Hyperuricemia, the heart, and the kidneys - to treat or not to treat?

Authors:  Tadej Petreski; Robert Ekart; Radovan Hojs; Sebastjan Bevc
Journal:  Ren Fail       Date:  2020-11       Impact factor: 3.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.